Last reviewed · How we verify
Fluticasone propionate 250
Fluticasone propionate is a corticosteroid that suppresses inflammatory and immune responses by binding to glucocorticoid receptors in target tissues.
Fluticasone propionate is a corticosteroid that suppresses inflammatory and immune responses by binding to glucocorticoid receptors in target tissues. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD).
At a glance
| Generic name | Fluticasone propionate 250 |
|---|---|
| Also known as | Fluticasone 250 |
| Sponsor | SkyePharma AG |
| Drug class | Inhaled corticosteroid (ICS) |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Pulmonology |
| Phase | Phase 3 |
Mechanism of action
Fluticasone propionate exerts its anti-inflammatory effects by binding to intracellular glucocorticoid receptors, which translocate to the nucleus and modulate gene expression of pro-inflammatory cytokines, chemokines, and adhesion molecules. This reduces recruitment and activation of inflammatory cells, decreasing local inflammation and immune responses. At the 250 mcg dose, it is typically used for inhaled delivery to treat respiratory inflammatory conditions.
Approved indications
- Asthma maintenance therapy
- Chronic obstructive pulmonary disease (COPD)
Common side effects
- Oropharyngeal candidiasis
- Dysphonia / hoarseness
- Tremor
- Headache
- Throat irritation
Key clinical trials
- Individualizing Treatment for Asthma in Primary Care (Full Study) (PHASE4)
- Individualizing Treatment for Asthma in Primary Care (PHASE4)
- A Non- Inferiority Comparative Study Between Seretide® and Salmeterol/Fluticasone Eurofarma in Patients with Asthma (PHASE3)
- Study of Fluticasone/Formoterol/Glycopyrronium for the Treatment Chronic Obstructive Pulmonary Disease (TRIPLAR) (PHASE3)
- Hyperpolarized Xenon-129 MRI: a New Multi-dimensional Biomarker to Determine Pulmonary Physiologic Responses to COPD Therapeutics (PHASE2)
- CIVETTA: Correlating Inflammatory Values of FEno, SympToms, SpuTum and Lung Function in Asthma (PHASE2)
- Effects of Mometasone Furoate Dry Powder Inhaler, Fluticasone Propionate, and Montelukast on Bone Mineral Density in Asthmatics (Study P03418) (PHASE4)
- Study of Inhaled Glucocorticosteroids/Long-Acting Bronchodilator Drugs in Subjects With Asthma That Have Been Taking Inhaled Glucocorticosteroids (Study P04705AM1) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fluticasone propionate 250 CI brief — competitive landscape report
- Fluticasone propionate 250 updates RSS · CI watch RSS
- SkyePharma AG portfolio CI